Molecular Regulation of Hepatic Transporters
Molecular Regulation of Hepatic Transporters
批准号:
7800419
负责人:
SAUL J. KARPEN
金额:
$27.92万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-01 至 2011-10-20
关键词:
AbbreviationsAcuteAcute-Phase ReactionAnionsAnti-Inflammatory AgentsAttenuatedBile AcidsBile fluidBindingCarrier ProteinsCationsCholestasisCholesterolCholic AcidsChronicCurcuminDataDeoxycholic AcidDexamethasoneDigestive System DisordersDirect RepeatsEffectivenessEnhancersFunctional disorderGene ExpressionGene ProteinsGenesGlucocorticoidsGlutathione S-TransferaseGoalsHepaticHepatobiliaryHepatocyteIn VitroIndividualInflammationInflammatoryInterleukin-1InterventionKnock-outLigandsLinkLipopolysaccharidesLithocholic AcidLiverLiver diseasesLocationMAPK8 geneMAPK9 geneMG132MapsMediatingMediator of activation proteinMembraneMembrane ProteinsMitogen-Activated Protein KinasesModelingModificationMolecularMolecular TargetMulti-Drug ResistanceMusNuclearNuclear ExportNuclear ReceptorsP-GlycoproteinsPathway interactionsPhospholipidsPhosphorylationPhosphotransferasesPhysiologicalPhysiologyPost-Translational Protein ProcessingPost-Translational RegulationProteasome InhibitionProteasome InhibitorProteinsPumpRXRReactionRegulationResearch PersonnelRetinoic Acid ReceptorReverse Transcriptase Polymerase Chain ReactionRoleSignal PathwaySignal TransductionSiteTestingTherapeutic InterventionTimeTranscription CoactivatorTranscription Factor AP-1Tumor Necrosis Factor-alphaTumor Necrosis FactorsUbiquitinUbiquitinationalitretinoinbasebile acid transporterbile saltscytokinedesignextracellularfunctional disabilityhepatocyte nuclear factorin vitro Modelin vivoinhibitor/antagonistmacromolecular assemblymembermulticatalytic endopeptidase complexnon-genomicnovel therapeuticspolypeptidepregnane X receptorpromoterprotein activationprotein expressionreceptorresearch studyresponserosiglitazonestress-activated protein kinase 1transcription factor
中文摘要
肝脏对炎症反应的中心特征之一是抑制一系列广泛的
英文摘要
One of the central features of the hepatic response to inflammation is the suppression of a broad array of
core physiological functions, including those essential to maintaining hepatobiliary transport of bile acids. In
addition to post-translational regulation of transporter protein membrane expression and function,
inflammation-based cell signaling pathways act on nuclear targets to transcriptionally suppress the
expression of the essential bile acid transporters Ntcp and Bsep. The central Type II NR superfamily
member and heterodimer partner RXRa is a major transcriptional activator of these two genes, and its
nuclear activity is rapidly suppressed by inflammation-based cell signaling. Reduced RXRa target gene
expression leads to multiple functional impairments and damage to hepatocytes. How cell signaling
pathways suppress RXRa function is unknown, and forms the basis for the explorations and interventions
proposed in this application. The overall unifying hypothesis is that inflammatory cell signaling pathways
reduce nuclear activity of RXRa via a coordinated cascade of post-translational modification, nuclear export
and proteasomal degradation. The following four Aims will determine the underlying physiology, and
pathophysiology of inflammation-mediated cholestasis and explore novel therapeutics.
Aim 1: Define the molecular mechanisms mediating IL-1(3-induced nuclear export of RXRa.
Aim 2: Determine roles for ubiquitination and proteasomal degradation of RXRa in response to IL-1 IB-
induced signaling pathways.
Aim 3: Explore crosstalk between bile acid and IL-1p-mediated pathways that modify RXRa function.
Aim 4: Investigate the effects of anti-inflammatory agents on transporter gene and protein expression in
the IPS model of hepatic inflammation.
It is through a combined in vitro and in vivo approach that we can explore the mechanisms, mediators, and
potential therapeutic interventions aimed at restoring RXRa function, hepatobiliary transporter function, and
bile flow, in the setting of inflammation-mediated cell signaling in liver. The ultimate goal of these studies is
to provide rational molecular targets for the testing of therapies specifically designed to interfere with the
damaging consequences of inflammation-mediated pathways, which are engaged in nearly all forms of acute
and chronic liver diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modeling genetic contributions to biliary atresia
-
批准号:10639240
-
项目类别:
-
资助金额:$64.01万
-
财政年份:2023
-
负责人:SAUL J. KARPEN
-
依托单位:
Research Training in Translational Gastroenterology and Hepatology
-
批准号:10410926
-
项目类别:
-
资助金额:$7.65万
-
财政年份:2016
-
负责人:SAUL J. KARPEN
-
依托单位:
Research Training in Translational Gastroenterology and Hepatology
-
批准号:9073070
-
项目类别:
-
资助金额:$15.23万
-
财政年份:2016
-
负责人:SAUL J. KARPEN
-
依托单位:
Research Training in Translational Gastroenterology and Hepatology
-
批准号:9280922
-
项目类别:
-
资助金额:$29.23万
-
财政年份:2016
-
负责人:SAUL J. KARPEN
-
依托单位:
A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF CORTICOSTEROID THERAPY
-
批准号:8356692
-
项目类别:
-
资助金额:$0.67万
-
财政年份:2010
-
负责人:SAUL J. KARPEN
-
依托单位:
The Childhood Liver Disease Research and Education Network (ChilDREN)
-
批准号:8011891
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2010
-
负责人:SAUL J. KARPEN
-
依托单位:
CHOLESTATIC LIVER DISEASE CONSORTIUM (CLIC): LONGITUDINAL STUDY OF GENETIC CAUSE
-
批准号:8356694
-
项目类别:
-
资助金额:$0.79万
-
财政年份:2010
-
负责人:SAUL J. KARPEN
-
依托单位:
BARC: BILLIARY ATRESIA STUDY IN INFANTS AND CHILDREN (BASIC)
-
批准号:8356678
-
项目类别:
-
资助金额:$2.22万
-
财政年份:2010
-
负责人:SAUL J. KARPEN
-
依托单位:
BILIARY ATRESIA RESEARCH CONSORTIUM (BARC): A PROSPECTIVE DATABASE OF INFANT
-
批准号:8356666
-
项目类别:
-
资助金额:$3.26万
-
财政年份:2010
-
负责人:SAUL J. KARPEN
-
依托单位:
A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF CORTICOSTEROID THERAPY
-
批准号:8166708
-
项目类别:
-
资助金额:$0.85万
-
财政年份:2009
-
负责人:SAUL J. KARPEN
-
依托单位:
CHOLESTATIC LIVER DISEASE CONSORTIUM (CLIC): LONGITUDINAL STUDY OF GENETIC CAUSE
-
批准号:8166711
-
项目类别:
-
资助金额:$1.41万
-
财政年份:2009
-
负责人:SAUL J. KARPEN
-
依托单位:
Genome-Wide Analysis of RXR-alpha Binding In Mouse Liver Chromatin with ChIP-SEQ
-
批准号:8365292
-
项目类别:
-
资助金额:$24.06万
-
财政年份:2009
-
负责人:SAUL J. KARPEN
-
依托单位:
Genome-Wide Analysis of RXR-alpha Binding In Mouse Liver Chromatin with ChIP-SEQ
-
批准号:7942986
-
项目类别:
-
资助金额:$23.76万
-
财政年份:2009
-
负责人:SAUL J. KARPEN
-
依托单位:
BARC: BILLIARY ATRESIA STUDY IN INFANTS AND CHILDREN (BASIC)
-
批准号:8166684
-
项目类别:
-
资助金额:$2.55万
-
财政年份:2009
-
负责人:SAUL J. KARPEN
-
依托单位:
BILIARY ATRESIA RESEARCH CONSORTIUM (BARC): A PROSPECTIVE DATABASE OF INFANT
-
批准号:8166667
-
项目类别:
-
资助金额:$2.92万
-
财政年份:2009
-
负责人:SAUL J. KARPEN
-
依托单位:
Genome-Wide Analysis of RXR-alpha Binding In Mouse Liver Chromatin with ChIP-SEQ
-
批准号:7815984
-
项目类别:
-
资助金额:$40.91万
-
财政年份:2009
-
负责人:SAUL J. KARPEN
-
依托单位:
BARC: BILLIARY ATRESIA STUDY IN INFANTS AND CHILDREN (BASIC)
-
批准号:7950630
-
项目类别:
-
资助金额:$1.19万
-
财政年份:2008
-
负责人:SAUL J. KARPEN
-
依托单位:
CHOLESTATIC LIVER DISEASE CONSORTIUM LONGITUDINAL STUDY
-
批准号:7950664
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2008
-
负责人:SAUL J. KARPEN
-
依托单位:
BILIARY ATRESIA RESEARCH CONSORTIUM (BARC): A PROSPECTIVE DATABASE OF INFANT
-
批准号:7950607
-
项目类别:
-
资助金额:$2.41万
-
财政年份:2008
-
负责人:SAUL J. KARPEN
-
依托单位:
A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF CORTICOSTEROID THERAPY
-
批准号:7950661
-
项目类别:
-
资助金额:$0.12万
-
财政年份:2008
-
负责人:SAUL J. KARPEN
-
依托单位:
海外基金